Dr. John Cush RheumNow
2 years 3 months ago
Predicting CKD Outcomes in Lupus Nephritis
An observational cohort study suggests that proteinuria levels in lupus nephritis (LN) patients did not predict their histologic class.
https://t.co/SCsuYuXgw4 https://t.co/bHB9ggf20H
Dr. John Cush RheumNow
2 years 3 months ago
1/3 of lupus nephritis patient classified as ""complete responders"" continued to accrue progressive renal damage despite resolution of proteinuria over 1 year.
Dr. @andreafava reviews GFR trajectories after renal bx at #RNL2024 @RheumNow https://t.co/mqwhfIFQsL
Dr. John Cush RheumNow
2 years 3 months ago
#RNL2024
@DrDavidKarp
Incomplete lupus is heterogeneous term
""Stage 2"" pre-classification stage as ILE/UCTD
Stage 1: non-specific antibodies, dysregulation
2: incomplete features
3: classified, multi-system disease
4: irreversible tissue damage https://t.co/lmorwojG49
Dr. John Cush RheumNow
2 years 3 months ago
Urine proteomics in lupus nephritis
IL-16 and CD163 are urinary biomarkers most correlated w/ histologic activity
Myeloid & degranulation sign ass w histo activity -> PR3+cells abundant in LN
@andreafava #RNL2024 @RheumNow https://t.co/YpoMiupOlQ
Dr. Jack Cush reviews this past week’s news and journal articles from RheumNow.com.
Dr. John Cush RheumNow
2 years 3 months ago
Venous thromboembolic event Risk study in 1854 SLE pts vs controls (12,107) from 1985–2015 in W Australia. VTE affected 12.8% SLE pts; 6 fold higher than controls (RR 6.6). Risk factors: aPL(aHR 4.24), serositis (2.7), nephritis (1.75), low Plts (1.65) https://t.co/KNInhNkjmQ https://t.co/jT3cTemxMD
Dr. John Cush RheumNow
2 years 3 months ago
Our final TNR for the month of April will take place on 4/30 at 6:30pm ET.
Mastering SLE
Rethinking Pre-Clinical Disease in Lupus - David Karp, MD
Biology and Rx of Lupus Flares - Michelle Kahlenberg, MD
Current/Future Biomarkers in SLE - Andrea Fava, MD
https://t.co/IoRDAaAJbo https://t.co/C7HpKvehXX
Dr. John Cush RheumNow
2 years 3 months ago
Prospective look at 25 280 older adults (mean 74yrs) w/ incident fracture, shows impact of multimorbidity by Charlson Comorbid Index (CCI). If CCI =2-3, Incr risk of subseq Fx (16-25%) & death (HR ~2); If CCI=4+, Fx Risk ^33-48%, death HR~4. https://t.co/6wnhFNiSXH https://t.co/Xy2y0ANDRd
Dr. John Cush RheumNow
2 years 3 months ago
Prevalence of MSK presentations in practice = 21.1%, based on UK practice cohort. Most common: pain in LS spine (18%) & knee (17%). Re-presentations of existing Dx made up 74% all MSK consultations. Steroid injx given to 1/3 of knee consults https://t.co/nTioq1lCEB https://t.co/ecm8Kxz2cu
Dr. John Cush RheumNow
2 years 3 months ago
JAMA review of ILD; that affects 650,000 in USA, leading to 25,000-30,000 deaths/YR. Types reviewed. Key Symptoms: dyspnea and cough, w/ chest CT being diagnostic tool. Antifibrotic & immunomodulatory may slow disease progression. https://t.co/xegChTUysM https://t.co/6GMJCqjoBx
Machine learning (ML) models were applied to 3 cohorts of lupus nephritis (LN) patients and established algorithms to predict co-infection in LN. This study analyzed 111 non-infected LN patients, 72 infected LN patients, and 206 healthy controls (HCs), looking at patient demographics, infection outcomes, medication, and laboratory indexes (including cell counts and lymphocyte subsets).
Dr. John Cush RheumNow
2 years 3 months ago
Is Colchicine Rx a problem? Retrospective study of UK Clinical Practice registry, 13945 gout initiated allopurinol with colchicine (64yrs; 78% male). 26% on 1+ meds interacting w/ colchicine. Diarrhea & MI more freq w/ comorbidities & more severe CKD https://t.co/Y2boo9gcg2 https://t.co/aqUGMooXto
Dr. John Cush RheumNow
2 years 4 months ago
Self Acupressure in Knee Osteoarthritis
A clinical trial has shown that self-administered acupressure (SAA) is effective in relieving knee osteoarthritis (KOA) patients.
https://t.co/jwP25u7J0b https://t.co/PH3aOoJaDu
